Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic

This article was originally published in The Gray Sheet

Executive Summary

Gem II VR (Model 7229) single-chamber implantable cardioverter defibrillator is released in the U.S. and internationally following FDA approval July 27 of a premarket approval application supplement, the company reports July 29. The 39 cc, 77 gram device offers full-energy (30 Joules) and high-energy (35 Joules) options for ventricular rate responsive pacing therapy and is 20% smaller than its predecessor, the 48 cc Gem ICD. Competitors include Guidant (39 cc Mini IV single-chamber ICD/pacer), St. Jude (single-chamber, 34 cc Profile MD ICD), and Angeion (47 cc single-chamber Lyra 2020 ICD)

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012123

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel